Adaptimmune Therapeutics (ADAP)
NASDAQ: ADAP
· Real-Time Price · USD
0.28
-0.00 (-1.06%)
At close: Jun 09, 2025, 3:58 PM
-1.06% (1D)
| Bid | 0.28 |
| Market Cap | 72.84M |
| Revenue (ttm) | 179.64M |
| Net Income (ttm) | -69.89M |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -0.94 |
| Forward PE | -2.04 |
| Analyst | n/a |
| Ask | 0.32 |
| Volume | 655,882 |
| Avg. Volume (20D) | 1,843,711 |
| Open | 0.30 |
| Previous Close | 0.28 |
| Day's Range | 0.28 - 0.30 |
| 52-Week Range | 0.20 - 1.48 |
| Beta | 2.25 |
About ADAP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ADAP
Website n/a
3 months ago
-15.31%
ADAP stock has given up its prior gain. Adaptimmun...
Unlock content with
Pro Subscription
3 months ago
-15.31%
Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
3 months ago · seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call TranscriptAdaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Ci...
3 months ago · newsfilecorp.com
Adaptimmune Reports Q1 Financial Results and Provides Business UpdateTECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45...
5 months ago · seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call TranscriptAdaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Of...
